Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vertex Pharmaceuticals
(NQ:
VRTX
)
500.25
+4.82 (+0.97%)
Streaming Delayed Price
Updated: 1:59 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
58
59
Next >
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
January 22, 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD.
Via
Talk Markets
A New S&P 500 Bull Market Just Began: 3 No-Brainer Stocks to Buy Hand Over Fist
January 22, 2024
These stocks seem likely to keep up their winning ways.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
10 Health Care Stocks Whale Activity In Today's Session
January 22, 2024
Via
Benzinga
Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
January 22, 2024
Via
Benzinga
If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today
January 22, 2024
Has investing in Vertex been a better option than just putting your money in the S&P 500?
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Market Whales and Their Recent Bets on VRTX Options
January 17, 2024
Via
Benzinga
The Best Stock to Invest $1,000 in Right Now
January 17, 2024
This stock has what it takes to be a big winner.
Via
The Motley Fool
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals
January 11, 2024
Via
Benzinga
Cathie Wood's Flagship ARKK ETF Is Taking On Water Due To Coinbase, Tesla, These Stocks
January 22, 2024
The flagship ETF's top holdings are down in 2024, especially No. 1 Coinbase.
Via
Investor's Business Daily
Topics
ETFs
2 Smart Growth Stocks to Buy Hand Over Fist in 2024
January 21, 2024
These businesses are on paths to extremely bright futures.
Via
The Motley Fool
3 Unstoppable Growth Stocks That Can Make You Richer in 2024
January 20, 2024
These big winners of 2023 could keep their momentum going in the new year.
Via
The Motley Fool
These 2 Phenomenal Growth Stocks Can Make You Richer in 2024
January 20, 2024
One market-beating stock and one beaten-down stock look like tempting buys for very different reasons.
Via
The Motley Fool
3 High-Flying Stocks That Could Soar Even More in 2024
January 20, 2024
These big winners could keep the momentum going.
Via
The Motley Fool
Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
January 17, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
January 17, 2024
FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the...
Via
Benzinga
Exposures
Product Safety
Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock
January 16, 2024
Shares of Vertex have risen exponentially since last month. Crispr stock, though, is meandering.
Via
Investor's Business Daily
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
January 16, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
January 16, 2024
Via
Benzinga
Here's Why CRISPR Therapeutics Stock Rose 54% Last Year
January 15, 2024
Key regulatory developments sent this biotech stock higher.
Via
The Motley Fool
Down 88%, Could Editas Medicine Be a Good Investment Now?
January 15, 2024
The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles.
Via
The Motley Fool
My 3 Highest-Conviction Growth Stocks to Buy in 2024
January 14, 2024
Simply put, these stocks inspire confidence.
Via
The Motley Fool
3 Growth Stocks to Buy That Could Be Massive Long-Term Winners
January 14, 2024
These stocks appear to have what it takes to keep up their winning ways.
Via
The Motley Fool
3 Unstoppable Stocks to Buy in 2024
January 13, 2024
These stocks appear to be on a clear path to continued growth.
Via
The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week
January 13, 2024
These companies could stand out thanks to game-changing technology.
Via
The Motley Fool
Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
January 12, 2024
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Uber Technologies, Inc. (NYSE: UBER) shares hit an all-time high on Thursda
Via
Benzinga
3 Stocks to Buy in the Booming Field of Gene Editing
January 11, 2024
As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.
Via
InvestorPlace
Should Quality-Oriented Investors Explore VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)?
January 11, 2024
Reasonable growth and debt and a high ROIC for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX).
Via
Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
January 10, 2024
Via
Benzinga
2 Red Flags for Bluebird Bio Stock
January 10, 2024
The biotech's struggles may continue.
Via
The Motley Fool
These 3 Stocks Have Beaten the S&P Average Return for Years and Are Likely to Continue That Trend
January 10, 2024
These winners seem likely to keep up their winning ways.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
58
59
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.